ArticleArthritis research & therapy2005
Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen.
Article in Arthritis research & therapy, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Inflammatory myopathies overlapping with systemic sclerosis: a systematic review.Clinical rheumatology · 2022Pooled it
- Muscle involvement in systemic sclerosis: points to consider in clinical trials.Rheumatology (Oxford, England) · 2017Pooled it
- Case report: Clinical, genetic and immunological characterization of a novelFrontiers in genetics · 2024Article
- Anti-U11/U12 Antibodies as a Rare but Important Biomarker in Patients with Systemic Sclerosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2023Review
- Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis.Frontiers in immunology · 2022Review
- An Anti-PM/Scl-75 Antibody-positive Japanese Woman Who Developed Inflammatory Myopathy.Internal medicine (Tokyo, Japan) · 2019Article
- Autoantibodies Associated With Connective Tissue Diseases: What Meaning for Clinicians?Frontiers in immunology · 2018Review
- Anti-PM/Scl antibodies are found in Japanese patients with various systemic autoimmune conditions besides myositis and scleroderma.Arthritis research & therapy · 2015Article
- Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis.Arthritis research & therapy · 2012Article
- Frequency of disease-associated and other nuclear autoantibodies in patients of the German Network for Systemic Scleroderma: correlation with characteristic clinical features.Arthritis research & therapy · 2011Article
- Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production.The FEBS journal · 2010Article
- Clinical and serological evaluation of a novel CENP-A peptide based ELISA.Arthritis research & therapy · 2010Article
- Antibodies against PM/Scl-75 and PM/Scl-100 are independent markers for different subsets of systemic sclerosis patients.Arthritis research & therapy · 2009Article
- The changing landscape of the clinical value of the PM/Scl autoantibody system.Arthritis research & therapy · 2009Article
- [Laboratory diagnostics for systemic sclerosis].Zeitschrift fur Rheumatologie · 2007Review
- Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus.Arthritis research & therapy · 2007Article
- Myositis specific autoantibodies.Current rheumatology reports · 2006Review
- Myositis-related interstitial lung disease and antisynthetase syndrome.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e TisilogiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-PM/Scl antibodies represent a specific serological marker for a subset of patients with scleroderma (Scl) and polymyositis (PM), and especially with the PM/Scl overlap syndrome (PM/Scl). Anti-PM/Scl reactivity is found in 24% of PM/Scl patients and is found in 3-10% of Scl and PM patients. The PM/Scl autoantigen complex comprises 11-16 different polypeptides. Many of those proteins can serve as targets of the anti-PM/Scl B-cell response, but most frequently the PM/Scl-100 and PM/Scl-75 polypeptides are targeted. In the present study we investigated the clinical relevance of a major alpha helical PM/Scl-100 epitope (PM1-alpha) using a newly developed peptide-based immunoassay and compared the immunological properties of this peptide with native and recombinant PM/Scl antigens. In a technical comparison, we showed that an ELISA based on the PM1-alpha peptide is more sensitive than common techniques to detect anti-PM/Scl antibodies such as immunoblot, indirect immunofluorescence on HEp-2 cells and ELISA with recombinant PM/Scl polypeptides. We found no statistical evidence of a positive association between anti-PM1-alpha and other antibodies, with the exception of known PM/Scl components. In our cohort a negative correlation could be found with anti-Scl-70 (topoisomerase I), anti-Jo-1 (histidyl tRNA synthetase) and anti-centromere proteins. In a multicenter evaluation we demonstrated that the PM1-alpha peptide represents a sensitive and reliable substrate for the detection of a subclass of anti-PM/Scl antibodies. In total, 22/40 (55%) PM/Scl patients, 27/205 (13.2%) Scl patients and 3/40 (7.5%) PM patients, but only 5/288 (1.7%) unrelated controls, tested positive for the anti-PM1-alpha peptide antibodies. These data indicate that anti-PM1-alpha antibodies appear to be exclusively present in sera from PM/Scl patients, from Scl patients and, to a lesser extent, from PM patients. The anti-PM1-alpha ELISA thus offers a new serological marker to diagnose and discriminate different systemic autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.